DEFA14A: Exact Sciences CEO on Strategic Abbott Merger

Exact Sciences CEO Kevin Conroy discusses the strategic benefits of the proposed acquisition by Abbott Laboratories, emphasizing global reach and shared values.

Summary

• Exact Sciences Corporation is undergoing a proposed acquisition by Abbott Laboratories.
• Kevin Conroy, President and CEO of Exact Sciences, released a pre-recorded video on November 20, 2025, discussing the transaction.
• Conroy highlighted Abbott's 137-year history as a patient-centric healthcare company with a focus on innovation, physician education, and health system partnerships.
• Both companies share similar Midwestern values, work ethic, and commitment to innovation, being located 100 miles apart.
• Exact Sciences is set to become Abbott's dedicated cancer diagnostics business, with its people responsible for continued growth.
• The acquisition is expected to significantly expand the global reach of Exact Sciences' advanced cancer diagnostics, including Cologuard, Cancerguard, Oncodetect, and Oncotype, leveraging Abbott's presence in serving 2 billion patients worldwide annually.
• Madison, Wisconsin, will remain Exact Sciences' headquarters under the Abbott brand, and its Cologuard and Cancer Guard labs in Wisconsin will not change.

Sentiment

Score: 8

Explanation: The CEO's remarks are overwhelmingly positive, highlighting significant strategic benefits, global expansion opportunities, and shared values. The legal disclaimers are standard for such merger announcements and do not detract from the positive framing of the transaction itself.

Positives

• Integration into Abbott, an iconic healthcare company with 137 years of experience and a patient-centric approach.
• Significant global expansion opportunities for Exact Sciences' cancer diagnostics (Cologuard, Cancerguard, Oncodetect, Oncotype) through Abbott's extensive international reach, serving 2 billion patients annually.
• Exact Sciences will become Abbott's dedicated cancer diagnostics business, allowing its team to continue driving growth in this specialized area.
• Shared corporate values, work ethic, and a focus on inspired innovation between the two Midwestern companies.
• Commitment to maintaining Exact Sciences' headquarters and its Cologuard and Cancer Guard labs in Madison, Wisconsin, preserving local operations and jobs.

Risks

• Possible inability of the parties to consummate the proposed transaction on a timely basis or at all.
• Potential inability to satisfy conditions precedent to consummation, including necessary regulatory approvals and the requisite vote by Exact Sciences stockholders.
• Risk of any event, change, or other circumstance occurring that could give rise to the termination of the Merger Agreement.
• Possibility that the Merger Agreement may be terminated in circumstances requiring Exact Sciences to pay a termination fee.
• Potential for competing offers to be made for Exact Sciences.
• Adverse impact on Exact Sciences from contractual restrictions under the Merger Agreement that limit its ability to pursue business opportunities or strategic transactions.
• Significant transaction costs associated with the proposed transaction and the possibility that it may be more expensive to complete than anticipated.
• Potential adverse effects of the announcement or pendency of the proposed transaction, or any failure to complete it, on the market price of Exact Sciences common stock.
• Adverse effects on Exact Sciences' ability to develop and maintain relationships with its personnel (including attracting and retaining highly qualified management and scientific personnel), customers, suppliers, and others.
• Diversion of management's attention from Exact Sciences' ongoing business operations due to the proposed transaction.
• Risk of litigation and/or regulatory actions related to the proposed transaction or Exact Sciences' business and the outcome of any such actions.

Future Outlook

The future outlook for Exact Sciences involves becoming Abbott's dedicated cancer diagnostics business, leveraging Abbott's global reach to expand access to advanced cancer tests worldwide, and continuing to grow its operations with its headquarters and labs remaining in Wisconsin.

Management Comments

• "What's fantastic about coming together with Abbott – becoming part of an iconic company – is they care about patients. They're a health care company. That's all they've done for 137 years."
• "They don't have a cancer diagnostics business, so we become that. And our people are responsible for continuing to grow."
• "Abbott has incredible reach all over the world. They serve 2 billion patients every year all over the globe. And so now we can bring our advanced cancer diagnostics, these tests to people outside of the US and all over the world."
• "Madison will remain Exact Sciences headquarters underneath the Abbott brand. Our lab won't change our lab for Cologuard and Cancer Guard here in Wisconsin."

Industry Context

This announcement reflects a trend of consolidation within the healthcare and diagnostics industry, where larger, diversified companies like Abbott seek to acquire specialized innovators to expand their product portfolios and global market presence. For Abbott, this acquisition establishes a significant footprint in the rapidly growing cancer diagnostics sector, while for Exact Sciences, it provides access to a vast international distribution network and resources of a global healthcare leader.

Legal Proceedings

• Risk of litigation and/or regulatory actions related to the proposed transaction or Exact Sciences' business.

Stakeholder Impact

• Shareholders: Will be required to vote on the proposed transaction and may experience significant influence on share price due to the acquisition.
• Employees: Exact Sciences employees will become part of Abbott, with the company's headquarters and labs remaining in Wisconsin, potentially offering new growth opportunities within a larger global entity.
• Patients: Expected to benefit from expanded global access to Exact Sciences' advanced cancer diagnostics through Abbott's extensive international reach.
• Customers and Suppliers: May experience changes in relationships and operational dynamics as Exact Sciences integrates into Abbott's structure.

Next Steps

• Exact Sciences will file a proxy statement with the U.S. Securities and Exchange Commission (SEC) regarding the proposed transaction.
• The definitive proxy statement will be sent or provided to Exact Sciences stockholders.
• Exact Sciences may file other documents with the SEC regarding the proposed transaction.
• Exact Sciences stockholders will be urged to read the proxy statement and any other relevant documents filed with the SEC carefully.
• Exact Sciences stockholders will vote on the proposed transaction.

Key Dates

Keywords

Exact Sciences, Abbott Laboratories, Acquisition, Merger, Cancer Diagnostics, Cologuard, Healthcare, Global Expansion, Oncotype, Corporate Governance